Arkin Holdings, Phoenix Group unite again on $140M biotech fund

Pini Orbach, Ph.D., Arkin Holdings’ head of pharma, will manage the new fund. (Arkin Holdings)

Four years after teaming up on a $60 million partnership to fund biotech and pharma companies, Israel’s Arkin Holdings and Phoenix Group are at it again. This time, the duo, along with Migdal, are committing $140 million in their second partnership, dubbed Arkin Bio-Ventures II. 

Pini Orbach, Ph.D., Arkin Holdings’ head of pharma, and Alon Lazarus, the company’s biotech investment manager will run the new fund. The plan is to divvy the $140 million in capital commitments between 10 to 12 private companies working on cutting-edge treatments, such as gene therapy, RNA- or DNA-based treatments and targeted therapies for conditions that have limited or no treatments, Arkin said in a statement. 

The fund’s predecessor, Arkin Bio-Ventures, has invested in startups tackling a range of disease areas, including metabolic disease, cancer and neurological and psychiatric disorders. Its portfolio includes cancer players Oncorus, Lutris Pharma, BioSight and UroGen. It recently chipped into Werewolf Therapeutics’ $56 million series A round. 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Frazier closes $617M life sciences fund, creating scope for bigger bets 

“Inspired by recent scientific breakthroughs, Arkin Bio-Ventures II is well-positioned to meaningfully expand its pharma investment capabilities and global reach, to capture innovative technologies and companies that could have a strong impact on medicine and provide new therapies for patients,” Orbach said in the statement. 

Arkin Bio-Ventures II comes soon after Andreessen Horowitz raised its third bio fund and Frazier Healthcare Partners netted $617 million for its tenth fund. At $750 million, A16z’s Bio Fund III dwarfed its predecessors, which totaled $650 million together. 

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.